Effect of Acute Supplementation (taurine) on Maximal Strength and Anaerobic Power
Launched by UNIVERSITY OF CENTRAL LANCASHIRE CYPRUS · Mar 13, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this study is to further investigate any potential ergogenic effects offered by taurine, under specific conditions, namely that of acute supplementation, as opposed to the chronic supplementation protocols of many popular ergogenic aids, such as creatine and beta alanine. Exercise modes investigated include maximal isometric strength, maximal instantaneous power generation, and sustained maximal anaerobic power output, investigated via grip strength, vertical jump height, and the Wingate test, respectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • participants 18 - 40 years of age
- • physically active or recreationally active with consistent training more than 3 times per week for at least 6 months
- • non-smokers
- Exclusion Criteria:
- • cardiovascular, respiratory or metabolic diseases
- • any musculoskeletal injury in the last six months
- • taking taurine and/or creatine supplementation in the past three months
About University Of Central Lancashire Cyprus
The University of Central Lancashire Cyprus (UCLan Cyprus) is a distinguished academic institution dedicated to advancing research and innovation in the field of health sciences. As a clinical trial sponsor, UCLan Cyprus leverages its expertise in medical research to design, implement, and oversee clinical trials that aim to improve healthcare outcomes. With a commitment to ethical standards and rigorous scientific methodologies, the university fosters collaborations with healthcare professionals and industry partners, ensuring that its clinical research contributes to evidence-based practices and the development of novel therapeutic interventions. UCLan Cyprus is dedicated to enhancing patient care through impactful research that addresses pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Larnaca, Pyla, Cyprus
Patients applied
Trial Officials
Efstathios Christodoulides, PhD
Principal Investigator
https://www.uclancyprus.ac.cy/
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported